B Chronic Lymphocytic LeukemiaNCT07337967
Reticulocyte Parameters as Early Indicators of Bone Marrow Erythropoietic Activity in Chronic B Lymphoproliferative Neoplasms
An observational study of B Chronic Lymphocytic Leukemia, run by Huda Ahmed Abdelsabour Abdelwahab.
Trial summary
Reticulocyte parameters as early indicators of bone marrow erythropoietic activity in chronic B lymphoproliferative neoplasms Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- B Chronic Lymphocytic Leukemia
- How many people
- 120 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2026to 1 Sep 2027
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Newly diagnosed adult patients with Chronic B LymphoPoliferative neoplasm according to WHO classification.
Who may be able to join
- Newly diagnosed adult patients with Chronic B LymphoPoliferative neoplasm according to WHO classification.
Who cannot join
- 1) Patients received chemotherapy.
- Patients with Active bleeding
- Patients with recent blood transfusion (less than 2 weeks).
- Patients on haematinics or vitamin B 12 therapy
About this study
Reticulocyte parameters as early indicators of bone marrow erythropoietic activity in chronic B lymphoproliferative neoplasms
- Conditions
- B Chronic Lymphocytic Leukemia
- Medical subject headings
- Leukemia, B-Cell
What is being measured
The primary outcome is the main question the study is designed to answer.
Reticulocyte count
Absolute peripheral blood reticulocyte count measured in patients with chronic B-cell lymphoproliferative disorders (CLPDs).
Unit of Measure: ×10⁹/L
Measured: 1 year
Reticulocyte percentage
Percentage of reticulocytes among total red blood cells in peripheral blood of patients with CLPDs.
Unit of Measure: %
Measured: 1 year
Immature reticulocyte fraction (IRF)
Proportion of immature reticulocytes in peripheral blood measured in patients with CLPDs.
Unit of Measure: %
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jan 2026
- Study start1 Jan 2026 (estimated)
- Primary completion1 Feb 2027 (estimated)
- Study completion1 Sep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for B Chronic Lymphocytic LeukemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 120 participants (estimated)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- Huda Ahmed Abdelsabour Abdelwahab
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Huda Ahmed Abdelsabour Abdelwahab, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07337967
- Sponsor's protocol ID
- AUN-FOM-CP-CLPD-RETIC-2025
- Status last verified
- Dec 2025
- First submitted
- 13 Dec 2025
- Last updated
- 13 Jan 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Reticulocyte Parameters as Early Indicators of Bone Marrow Erythropoietic Activity in Chronic B Lymphoproliferative Neoplasms
- ClinicalTrials.gov ID
- NCT07337967
- Acronym / sponsor ID
- AUN-FOM-CP-CLPD-RETIC-2025
- Conditions
- B Chronic Lymphocytic Leukemia
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Huda Ahmed Abdelsabour AbdelwahabUniversity, hospital or other
- Study start
- 1 Jan 2026 (estimated)
- Primary completion
- 1 Feb 2027 (estimated)
- Study completion
- 1 Sep 2027 (estimated)
- First posted
- 13 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Reticulocyte parameters as early indicators of bone marrow erythropoietic activity in chronic B lymphoproliferative neoplasms
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Target follow-up
- 1 Year
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Newly diagnosed adult patients with Chronic B LymphoPoliferative neoplasm according to WHO classification.
Key inclusion criteria (1 listed)
- Newly diagnosed adult patients with Chronic B LymphoPoliferative neoplasm according to WHO classification.
Key exclusion criteria (4 listed)
- 1) Patients received chemotherapy.
- Patients with Active bleeding
- Patients with recent blood transfusion (less than 2 weeks).
- Patients on haematinics or vitamin B 12 therapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Reticulocyte count
Time frame: 1 year
Absolute peripheral blood reticulocyte count measured in patients with chronic B-cell lymphoproliferative disorders (CLPDs). Unit of Measure: ×10⁹/L
Reticulocyte percentage
Time frame: 1 year
Percentage of reticulocytes among total red blood cells in peripheral blood of patients with CLPDs. Unit of Measure: %
Immature reticulocyte fraction (IRF)
Time frame: 1 year
Proportion of immature reticulocytes in peripheral blood measured in patients with CLPDs. Unit of Measure: %
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jan 2026.
Related trials for B Chronic Lymphocytic Leukemia
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Not yet recruitingPhase 2
Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
RecruitingObservational study
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma
RecruitingPhase 3
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic
RecruitingObservational study
HPC Offered for PRESERVE Expansion
Bone Marrow Transplant (BMT)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of B Chronic Lymphocytic Leukemia, run by Huda Ahmed Abdelsabour Abdelwahab.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 13 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Reticulocyte count (time frame: 1 year). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jan 2026.